Back to top
more

Cardiovascular Systems, Inc. (CSII)

(Delayed Data from NSDQ)

$39.49 USD

39.49
435,746

+1.98 (5.28%)

Updated May 3, 2019 04:00 PM ET

After-Market: $39.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Cardiovascular Systems (CSII) Introduces Diamondback in Canada

The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected

Strength in both coronary and peripheral segments drove Cardiovascular Systems' (CSII) revenues in the fiscal fourth quarter.

Cardiovascular Systems (CSII) Reports Q4 Loss, Tops Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 17.65% and 2.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Cardiovascular Systems (CSII) Report Negative Earnings Next Week? What You Should Know

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips

Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.

Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable

Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.

Cardiovascular Systems (CSII) Q3 Loss Widens, Gross Margin Dips

Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.

Cardiovascular Systems (CSII) Reports Q3 Loss, Misses Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -50.00% and -0.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Inks Deal to Enhance Patient Care

Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.

Debanjana Dey headshot

5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic

Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.

Cardiovascular Systems' (CSII) New Buyout Boosts CAD/PAD Line

Cardiovascular Systems' (CSII) acquisition of Peripheral Support Catheters will enhance outcomes for patients undergoing complex peripheral and coronary interventions.

Cardiovascular Systems' (CSII) WIRION Cures 1st U.S Patient

Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.

Cardiovascular Systems (CSII) Down 2.8% Since Last Earnings Report: Can It Rebound?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe

Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.

Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2

Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.

Cardiovascular Systems (CSII) Reports Break-Even Earnings for Q2

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 100.00% and -1.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

4 MedTech Underperformers Poised for a Turnaround in 2021

Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.

Cardiovascular Systems' (CSII) OAS Gets CE Mark for Use in Europe

Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.

Debanjana Dey headshot

5 MedTech Stocks That Have Outperformed the Industry in 2020

Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.

3 MedTech Growth Stocks With Solid Prospects for 2021

Here are a few MedTech growth stocks poised for a rebound that investors can scoop up to reap profits going into 2021.

Why Is Cardiovascular Systems (CSII) Down 4.4% Since Last Earnings Report?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Debanjana Dey headshot

4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success

Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.

Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 78.26% and 7.59%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Cardiovascular Systems (CSII) Q1 Earnings Expected to Decline

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.